SAN DIEGO, May 31, 2023 /PRNewswire/ -- Illumina, Inc. (NASDAQ: ILMN) announced today that it will host its third annual virtual Environment, Social and Corporate Governance (ESG) focused investor event at 9:00 am Pacific Time (12:00 pm Eastern Time), Monday, June 12, 2023.
Francis deSouza, Chief Executive Officer, Joydeep Goswami, Chief Financial Officer and Chief Strategy and Corporate Development Officer, Aimee Hoyt, Chief People Officer, Phil Febbo, M.D., Chief Medical Officer, John Frank, Chief Public Affairs Officer, and Sharon Vidal, Head of Corporate Social Responsibility, will be joined by Salli Schwartz, Vice President of Investor Relations for a presentation, fireside chat, and Q&A session for investors, analysts, and other interested parties regarding Illumina's ESG strategy and action plans.
Conference Call Details
The webcast will begin at 9:00 am Pacific Time (12:00pm Eastern Time) on Monday, June 12, 2023. Interested parties may register and access the live event through the Investor Info section of Illumina's website at investor.illumina.com or directly at Illumina Virtual ESG Investor Event. Attendees may submit questions in advance on the registration page.
To ensure timely connection, please join the webcast at least ten minutes before the scheduled start. A replay of the webcast will be posted on Illumina's website after the event and will be available for at least 30 days following.
About Illumina
Illumina is improving human health by unlocking the power of the genome. In 2023, we celebrate 25 years of innovation, which has established us as a global leader in DNA sequencing and array-based technologies, serving customers in the research, clinical and applied markets. Our products are used for applications in the life sciences, oncology, reproductive health, agriculture and other emerging segments. To learn more, visit www.illumina.com and connect with us on Twitter, Facebook, LinkedIn, Instagram, TikTok and YouTube.
Investors:
Salli Schwartz
+1.858.291.6421
This email address is being protected from spambots. You need JavaScript enabled to view it.
Media:
David McAlpine
+1.347.327.1336
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$125.09 |
Daily Change: | 0.89 0.72 |
Daily Volume: | 1,077,457 |
Market Cap: | US$19.840B |
January 14, 2025 January 13, 2025 January 07, 2025 December 04, 2024 |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load